Consider a long position in Spruce Biosciences (SPRB), with a potential entry point below $100 per share, as it is seen as a high-conviction play with a potential $1,000 long-term price target. For a turnaround opportunity, look at Sarepta Therapeutics (SRPT), which is considered a long-term buy for patient investors after it spends another quarter or two rebuilding market trust. Conversely, the quantum computing sector is presented as a high-conviction short opportunity, viewed as a speculative bubble detached from fundamentals. Specific companies to consider shorting include D-Wave (QBTS), Rigetti (RGTI), and BTQ, which are all expected to decline significantly over the long term. Investors should be cautious, as shorting these high-momentum stocks is risky and could lead to major short-term losses before the thesis plays out.

Spruce Biosciences (SPRB)

• The speaker is very confident in Spruce, which is sometimes called the "spruce moose".
• He mentions that if the stock were to fall below $100, he would buy more.
• Regarding FDA approval for their drug, the speaker believes it's a 50-50 chance on the first attempt. However, he thinks the chance of approval on the second attempt is 100%, as it would likely not require a new trial, but rather a fix for manufacturing issues.
• A potential delay in filing for approval from Q1 to Q2 or Q3 is seen as possibly better than filing and getting rejected.
• The speaker believes SPRB could be a $1,000 stock but adds that he likes to be conservative. He originally bought it after it received a breakthrough designation, believing it could 10x from that point.

Takeaways

• The sentiment is strongly bullish on SPRB for the long term.
• The primary risk factor mentioned is the initial FDA approval, which is seen as a coin flip. A rejection on the first try is anticipated as a possibility, but ultimate approval is expected.
• A potential entry point is mentioned at a price below $100 per share.
• The speaker has a very high long-term price target of $1,000, indicating significant upside potential from his perspective, though he qualifies this as a conservative estimate.

Quantum Computing Sector

• The speaker describes the quantum sector as a "nonsense sector" but acknowledges its strong momentum, making it difficult to short in the near term.
• He states he is comfortable shorting these stocks because he believes he knows where they are headed in the long run (implying they will go down).
• He notes that the rally in these stocks is happening for "no reason" and that fundamentals are not important in the current market environment for this sector.
• The speaker is actively shorting the sector and mentions getting margin calls due to the powerful rally, which he calls "euphoric, crazy prices." He is adding to his short positions despite the losses.
• He believes the rally could take years to unwind, and investors need to be prepared for irrationality to persist for a long time.

Takeaways

• The sentiment is extremely bearish on the quantum computing sector as a whole, viewing it as a speculative bubble detached from fundamentals.
• The speaker is actively shorting stocks in this sector, including D-Wave (QBTS), Rigetti (RGTI), and IonQ (IONQ).
• Risk: The primary risk for short-sellers is the powerful, irrational momentum that can drive prices to extreme highs and persist for an extended period, causing significant losses and margin calls.
• The investment strategy discussed is to short these companies with the conviction that they will eventually fall significantly, but it requires the patience and capital to withstand a potentially long and painful rally.

D-Wave (QBTS)

• The speaker singles out D-Wave as a stock he particularly likes to short, calling it a "total scam" and a "dog shit company."
• He is actively adding to his short position in D-Wave, even as the stock rallies significantly.
• He notes the former CEO of D-Wave is selling stock, which he sees as unsurprising.

Takeaways

• The sentiment is exceptionally bearish. The speaker views D-Wave as the most fraudulent or overvalued company within the already speculative quantum sector.
• This is presented as a high-conviction short idea, but it carries all the risks of shorting a high-momentum stock.

Rigetti (RGTI)

• The speaker describes Rigetti as a "shit show" where the founder quit and the company was almost bankrupt.
• He is confused as to why the stock has become a market darling, stating there is "no reason" for its rally.
• He mentions that the company's management itself seems confused about the stock's appreciation.

Takeaways

• The sentiment is strongly bearish, based on the company's troubled history and lack of fundamental justification for its current valuation.
• Like other quantum stocks, this is presented as a short idea, but one that is currently caught in an irrational market rally.

BTQ

• The speaker is extremely bearish on BTQ, stating it is going to "get clobbered."
• He calls it "completely useless" and a "total zero," predicting it is "going to zero."
• He notes that BTQ is just a startup and that his own private company, Godel, has more revenue.

Takeaways

• The sentiment is extremely bearish. The speaker sees no value in the company and expects it to fail completely.
• This is a high-conviction short idea based on the view that the company has no viable business.

Johnson & Johnson (JNJ)

• The analysis includes a review of JNJ's Q3 2025 earnings call.
• Overall Performance: Sales grew 5%, which the speaker notes is barely above inflation.
• Drug Portfolio:
  • Carvykti: "Really killing it," with the potential to become a $3 billion drug.
  • Stelara: Facing significant decline due to biosimilar competition.
  • IcoTropimra: A new oral drug for psoriasis that JNJ is very excited about, seeing it as a potential $5 billion+ brand that could set a "new standard of care."
• MedTech Business:
  • The Orthopedics division has returned to growth after struggling.
  • JNJ is focusing its MedTech strategy on vision, cardiovascular, and robotic surgery.
  • They plan to submit their Otava soft tissue robotic system to the FDA in the first half of 2026.

Takeaways

• The sentiment is mixed but leans neutral to slightly positive, acknowledging both headwinds and major growth drivers.
• Headwind: The major drug Stelara is declining due to competition, which is a drag on overall growth.
• Growth Drivers: The company has strong performers like Carvykti and a massive potential blockbuster in IcoTropimra. The MedTech division is also showing signs of a turnaround and has a clear strategic focus.
• Investors should watch the launch and adoption of IcoTropimra and the progress of the Otava robotic system as key future catalysts.

Sarepta Therapeutics (SRPT)

• The speaker states, "I still like Sarepta" and considers it a "long term long."
• He notes that the company is currently in the "doghouse" with Wall Street and needs a quarter or two to regain trust after a recent unspecified screw-up.
• He believes they will get approval for their drug and generate revenue from it.

Takeaways

• The sentiment is bullish for the long term.
• This is presented as a turnaround play. The company has faced a setback and lost investor confidence, which could present a buying opportunity for patient investors.
• The key is to wait for the company to execute over the next few quarters to rebuild trust with the market.

Bitcoin (BTC)

• The speaker believes a portfolio based primarily around Bitcoin is "pretty crazy."
• He describes Bitcoin as a "bubble asset that can only really live and survive in a bubble."
• He questions where demand for Bitcoin will come from if more attractive investment opportunities arise or if there is a recession, suggesting capital would flow out and the price would fall "quite a lot."
• He also notes that the code base is still being updated and bugs are being fixed, challenging the idea that it is a "set and forget" piece of software.

Takeaways

• The sentiment is bearish/skeptical.
• The speaker views Bitcoin as a speculative asset whose value is highly dependent on a bubble-like environment with few other attractive investment options.
• He suggests that Bitcoin is vulnerable to a significant price drop during a recession or a shift in market sentiment toward other assets.

Other Mentioned Stocks

• OpenDoor (OPEN): Mentioned as "so sad" and a "flash in the pan," implying a negative view.
• ATYR: The speaker states it "cannot recover," indicating a very bearish outlook.
• Ultragenix (RARE): He thought it was "fairly valued" the last time he looked, suggesting a neutral stance with no significant upside or downside.
• CLSQ: Described as a "huge scam," indicating an extremely bearish view.
• Intel (INTC): The speaker is very dismissive, stating "Intel's screwed" and won't be making a competitive GPU "this century." The sentiment is very bearish.